About

Francisco Adrian is the Chief Scientific Officer at HiFiBiO Therapeutics. He is an accomplished scientist with 25 years of experience in drug discovery and pharmaceutical research and development. Francisco has authored over 40 peer-reviewed articles and presented his research at multiple international conferences.

Francisco’s career in drug discovery and development started at the Novartis Institute for Functional Genomics (GNF) in La Jolla, CA. During his tenure at GNF as a project leader for different kinase inhibitor programs, he discovered a novel class of highly specific allosteric kinase inhibitors, now marketed as Scemblix^® for the treatment of chronic myeloid leukemia.

Before joining HiFiBiO Therapeutics, Francisco worked as a Director at the Sanofi Oncology Division in Cambridge, MA. At Sanofi he led the research efforts for different small molecule and antibody programs in preclinical and clinical development stages. Two of these programs culminated with the approval of Inrebic^® and Sarclisa^® for the treatment of hematological malignancies.

Francisco received his M.S. degree in Organic Chemistry and Biochemistry and Ph.D. in Molecular Microbiology from the University of Zaragoza, Spain. His postdoctoral training was in Hemato-Immunology at the St Louis Hospital in Paris, where he studied tumor escape mechanisms from immunosurveillance. He was appointed Corresponding Academician at the Royal Academy of Medicine in Zaragoza in 2002.